{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:55:44Z","timestamp":1791294944429,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["L'Enc\u00e9phale"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1016\/j.encep.2008.12.001","type":"journal-article","created":{"date-parts":[[2009,2,11]],"date-time":"2009-02-11T20:09:56Z","timestamp":1234382996000},"page":"66-72","source":"Crossref","is-referenced-by-count":4,"title":["Nouvelle strat\u00e9gie pharmacologique dans la schizophr\u00e9nie\u00a0: les agonistes partiels des r\u00e9cepteurs dopaminergiques D2. Caract\u00e9ristiques principales de l\u2019aripiprazole"],"prefix":"10.1016","volume":"35","author":[{"given":"J.","family":"Costentin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.encep.2008.12.001_bib1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0026-895X(24)12171-2","article-title":"Gi protein modulation induced by a selective inverse agonist for the peripheral cannabinoid receptor CB2: implication for intracellular signalisation cross-regulation","volume":"55","author":"Bouabala","year":"1999","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.encep.2008.12.001_bib2","doi-asserted-by":"crossref","first-page":"22330","DOI":"10.1074\/jbc.272.35.22330","article-title":"A selective inverse agonist for central cannabinoid receptor inhibits mitogen activated protein kinase activation stimulated by insulin or insulin-like growth factor receptor I. Evidence for a new model of receptor\/ligand interaction","volume":"272","author":"Bouaboula","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.encep.2008.12.001_bib3","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high affinity, partial agonist at human dopamine D2 receptors","volume":"302","author":"Burris","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.encep.2008.12.001_bib4","doi-asserted-by":"crossref","first-page":"756","DOI":"10.4088\/JCP.v66n0613","article-title":"Switching out patients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole","volume":"66","author":"Brown","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.encep.2008.12.001_bib5","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0026-895X(25)08958-8","article-title":"Drug effects at guanine nucleotide binding protein linked receptors: thermodynamic interpretation of negative antagonism of receptor activation in the absence of ligand","volume":"41","author":"Costa","year":"1994","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.encep.2008.12.001_bib6","unstructured":"Costentin J. Revue des principaux arguments \u00e9tayant l\u2019hypoth\u00e8se d\u2019une hyperactivit\u00e9 dopaminergique dans la schizophr\u00e9nie. Actualit\u00e9s de la schizophr\u00e9nie. Presses Universitaires de France, coll. Psychiatrie ouverte. \u00c9d. P. Pichot, 1981. Chap. 11, p 169\u2013193."},{"key":"10.1016\/j.encep.2008.12.001_bib7","unstructured":"Costentin J. Principaux aspects biochimiques et pharmacologiques des r\u00e9cepteurs c\u00e9r\u00e9braux de la dopamine. Actualit\u00e9s de la schizophr\u00e9nie. Presses Universitaires de France, coll. Psychiatrie ouverte. \u00c9d. P. Pichot, 1981. Chap. 10, p 145\u2013168."},{"key":"10.1016\/j.encep.2008.12.001_bib8","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.biopsych.2006.04.010","article-title":"Aripipraole blocks reinstatement of cocaine seeking in an animal model of relapse","volume":"61","author":"Feltenstein","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.encep.2008.12.001_bib9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1527-3458.2003.tb00246.x","article-title":"BP897, a selective dopamine D3 receptor ligand with therapeutic potential for the treatment of cocaine addiction","volume":"9","author":"Garcia-Ladona","year":"2003","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.encep.2008.12.001_bib10","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/sj.bjp.0701196","article-title":"Evidence that antipsychotic drugs are inverse agonists at D2 dopamine receptors","volume":"121","author":"Hall","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.encep.2008.12.001_bib11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.brainresrev.2004.12.033","article-title":"The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence","volume":"49","author":"Heidbreder","year":"2005","journal-title":"Brain Res Brain Res Rev"},{"key":"10.1016\/j.encep.2008.12.001_bib12","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0091-3057(01)00746-8","article-title":"Molecular pharmacological and functional diversity of 5HT receptors","volume":"71","author":"Hoyer","year":"2002","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.encep.2008.12.001_bib13","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/alcalc\/agl037","article-title":"Effects of aripiprazole on alcohol intake in an animal model of high alcohol drinking","author":"Ingman","year":"2006","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.encep.2008.12.001_bib14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0022-3565(25)12799-7","article-title":"Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1piperaziny]-butyoxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597) on prolactine release from the rat anterior pituitary gland","volume":"277","author":"Inoue","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.encep.2008.12.001_bib15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0014-2999(96)00920-X","article-title":"Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked dopamine GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in rat striatum","volume":"321","author":"Inoue","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.encep.2008.12.001_bib16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(02)01532-7","article-title":"The antipsychotic aripiprazole is a potent partial agonist at the human 5HT1A receptor","volume":"441","author":"Jordan","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.encep.2008.12.001_bib17","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0022-3565(25)10600-9","article-title":"7-{4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy}-3, 4-dihydro-2(1H)-quinolinone (OPC-14597) a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and post-synaptic D2 receptor antagonistic activity","volume":"274","author":"Kikuchi","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.encep.2008.12.001_bib18","unstructured":"Landry Y, Bertrand C. Approche fonctionnelle de la caract\u00e9risation des ligands et des r\u00e9cepteurs, in pharmacologie mol\u00e9culaire 2nd Ed., 1993, Arnette, Eds Y. Landry, J.P. Gies p.\u00a07\u201329."},{"key":"10.1016\/j.encep.2008.12.001_bib19","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0893-133X(98)00099-2","article-title":"Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes","volume":"20","author":"Lawler","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.encep.2008.12.001_bib20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejphar.2004.04.028","article-title":"Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain","volume":"493","author":"Li","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.encep.2008.12.001_bib21","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S0006-3223(98)00187-5","article-title":"Serotonergic basis of antipsychotic drug effects in schizophrenia","volume":"44","author":"Lieberman","year":"1998","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.encep.2008.12.001_bib22","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/0091270003261901","article-title":"Pharmacokinetics, tolerability and safety of aripiprazole following multiple oral dosing in normal healthy volunteers","volume":"44","author":"Mallikaartjun","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.encep.2008.12.001_bib23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1046\/j.1471-4159.2000.0740347.x","article-title":"Mechanism of agonism and inverse agonism at serotonin 5HT1A receptors","volume":"74","author":"Mc Loughlin","year":"2000","journal-title":"J Neurochem"},{"key":"10.1016\/j.encep.2008.12.001_bib24","first-page":"51","article-title":"Aripiprazole a dopamine-serotonin stabilizer","author":"Mc Quade","year":"2002","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.encep.2008.12.001_bib25","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1152\/physrev.1998.78.1.189","article-title":"Dopamine receptors: from structure to function","volume":"78","author":"Missale","year":"1998","journal-title":"Physiol Rev"},{"key":"10.1016\/j.encep.2008.12.001_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(96)00350-0","article-title":"Inhibition by a putative antipsychotic quinolone derivative (OPC-14597) of dopaminergic neurons in the ventral tegmental area","volume":"310","author":"Momiyama","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.encep.2008.12.001_bib27","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF01244880","article-title":"Haloperidol increases prolactin release and cAMP formation, in vitro inverse agonism at dopamine D2 receptor","volume":"92","author":"Nilsson","year":"1993","journal-title":"J Neural Transm"},{"key":"10.1016\/j.encep.2008.12.001_bib28","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1021\/jm940608g","article-title":"Novel antipsychotic agents with dopamine autoreceptor agonist properties=synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxyl]-3, 4-dihydro-2(1H) quinolinone derivatives","volume":"41","author":"Oshiro","year":"1998","journal-title":"J Med Chem"},{"key":"10.1016\/j.encep.2008.12.001_bib29","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/22560","article-title":"Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist","volume":"400","author":"Pilla","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.encep.2008.12.001_bib30","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1124\/mol.56.5.858","article-title":"Inverse agonism and neutral antagonism at \u03b11a and \u03b11b adrenergic receptor subtypes","volume":"56","author":"Rossier","year":"1999","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.encep.2008.12.001_bib31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2174\/187152706784111551","article-title":"The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders","volume":"5","author":"Sokoloff","year":"2006","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.encep.2008.12.001_bib32","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00213-006-0621-y","article-title":"Interaction of the novel antipsychotic aripiprazole with the 5HT1A and 5HT2A receptors: functional receptor-binding and in vivo electrophysiological studies","volume":"190","author":"Stark","year":"2007","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.encep.2008.12.001_bib33","first-page":"53","article-title":"Agonism and inverse agonism at dopamine D2-like receptors","volume":"supp","author":"Strange","year":"1999","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.encep.2008.12.001_bib34","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s007020200033","article-title":"Partial dopamine agonists in the treatment of psychosis","volume":"109","author":"Tamminga","year":"2002","journal-title":"J Neural Transm"},{"key":"10.1016\/j.encep.2008.12.001_bib35","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0026-895X(25)10026-6","article-title":"Determination of \u03b12 adrenergic receptor activation of G protein: evidence for a precoupled receptor\/G protein state","volume":"45","author":"Tian","year":"1994","journal-title":"Mol Pharmacol"}],"container-title":["L'Enc\u00e9phale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001370060800314X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001370060800314X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T16:49:24Z","timestamp":1738946964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001370060800314X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["S001370060800314X"],"URL":"https:\/\/doi.org\/10.1016\/j.encep.2008.12.001","relation":{},"ISSN":["0013-7006"],"issn-type":[{"value":"0013-7006","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]}}}